viru
caus
coronaviru
diseas
reach
pandem
level
result
signific
morbid
mortal
affect
everi
inhabit
contin
larg
number
patient
requir
intens
care
threaten
overwhelm
healthcar
system
global
likewis
compel
need
diseas
sever
test
priorit
care
resourc
patient
elev
risk
mortal
integr
pointofcar
sever
score
clinic
decis
support
system
present
use
biomark
measur
creactiv
protein
crp
nterminu
pro
b
type
natriuret
peptid
ntprobnp
myoglobin
myo
ddimer
procalcitonin
pct
creatin
kinasemyocardi
band
ckmb
cardiac
troponin
ctni
sever
score
combin
multiplex
biomark
measur
risk
factor
statist
learn
algorithm
predict
mortal
sever
score
train
evalu
use
data
hospit
patient
wuhan
china
analysi
find
sever
score
significantli
higher
group
die
versu
group
discharg
median
interquartil
rang
score
respect
area
curv
ci
promis
initi
model
pave
way
pointofcar
sever
score
system
impact
patient
care
valid
extern
collect
clinic
data
clinic
decis
support
tool
strong
potenti
empow
healthcar
provid
save
live
priorit
critic
care
patient
high
risk
advers
outcom
pandem
coronaviru
diseas
caus
sever
acut
respiratori
syndrom
coronaviru
first
report
wuhan
hubei
china
decemb
march
world
health
organ
declar
outbreak
pandem
although
expect
substanti
underreport
case
particularli
person
milder
symptom
asymptomat
case
countri
low
test
volum
april
case
confirm
approxim
death
diseas
global
major
outbreak
us
itali
china
spain
symptom
nonspecif
infect
individu
may
develop
fever
cough
fatigu
short
breath
muscl
ach
diseas
develop
lead
sever
pneumonia
acut
respiratori
distress
syndrom
ard
myocardi
injuri
sepsi
septic
shock
death
median
incub
period
approxim
five
day
develop
symptom
within
day
larger
analysi
patient
report
hospit
rate
percent
icu
admiss
rate
percent
larg
number
patient
requir
intens
care
threaten
overwhelm
healthcar
system
around
world
need
diseas
sever
test
priorit
care
patient
elev
risk
mortal
manag
low
risk
patient
outpati
set
home
selfquarantin
biomark
test
provid
key
inform
health
diseas
statu
individu
includ
covid
analysi
hospit
patient
wuhan
china
common
complic
lead
death
acut
cardiac
injuri
ard
coagul
dysfunct
acut
kidney
injuri
biomark
cardiac
troponin
ctni
creactiv
protein
crp
ddimer
procalcitonin
pct
significantli
increas
die
versu
recov
prognost
valu
determin
area
curv
auc
respect
anoth
studi
data
death
found
respiratori
cardiac
hemorrhag
hepat
renal
damag
present
patient
respect
patient
increas
crp
ddimer
import
ddimer
prognost
factor
also
demonstr
odd
death
significantli
increas
level
greater
admiss
biomark
cardiac
failur
ntermin
probtyp
natriuret
peptid
ntprobnp
also
shown
predict
death
patient
commun
acquir
pneumonia
recent
studi
hospit
patient
report
patient
cardiac
injuri
patient
myocardi
damag
significantli
higher
level
crp
pct
creatin
kinasemyocardi
band
ckmb
ctni
nt
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
probnp
patient
cardiac
injuri
also
frequent
requir
noninvas
mechan
ventil
vs
invas
mechan
ventil
vs
experienc
higher
rate
complic
ard
vs
compar
patient
without
cardiac
injuri
ultim
patient
cardiac
injuri
higher
mortal
without
vs
given
data
other
recommend
elev
treatment
prioriti
aggress
patient
underli
cardiovascular
diseas
evid
cardiac
injuri
grow
bodi
clinic
evid
relat
diseas
sever
suggest
biomark
play
domin
role
score
system
identifi
patient
increas
risk
sever
diseas
mortal
multipl
commerci
avail
platform
diagnosi
base
molecular
detect
viral
rna
remain
signific
gap
determin
diseas
prognosi
respect
earli
identif
individu
elev
risk
mortal
identifi
monitor
risk
sever
complic
critic
resourc
plan
prognost
likewis
rule
andor
reduc
admiss
patient
low
risk
complic
safe
manag
selfquarantin
would
conserv
preciou
medic
resourc
surg
new
case
outbreak
clinic
decis
support
tool
develop
sepsi
diseas
sever
develop
diseas
sever
knowledg
score
system
diseas
sever
intric
link
biomark
test
point
care
base
labonachip
platform
access
integr
test
score
system
use
point
care
lowand
middleincom
countri
would
help
manag
diseas
global
basi
studi
describ
recent
work
toward
develop
programm
bio
nano
chip
pbnc
capac
learn
adapt
task
assess
diseas
sever
multiplex
multiclass
platform
demonstr
previous
detect
quantit
protein
biomark
small
molecul
cellular
marker
applic
oral
cancer
ovarian
cancer
prostat
cancer
drug
abus
cardiac
heart
diseas
trauma
previous
develop
cardiac
scorecard
system
predict
spectrum
cardiovascular
diseas
score
system
combin
multipl
risk
factor
biomark
measur
provid
person
report
rang
diseas
indic
diagnost
prognost
model
cardiac
well
acut
myocardi
infarct
heart
failur
new
studi
describ
leverag
past
experi
develop
clinic
decis
support
tool
effici
adapt
flexibl
platform
develop
prognost
test
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
paper
describ
custom
pointofcar
diagnost
tool
suitabl
measur
biomark
use
discrimin
patient
recov
vs
die
complic
terribl
diseas
work
detail
develop
multiparamet
protein
assay
diagnost
model
lend
inform
relat
sever
model
train
intern
valid
use
data
hospit
patient
wuhan
china
evalu
extern
case
studi
hospit
patient
spectrum
diseas
complic
shenzhen
china
knowledg
effort
first
quantit
pointofcar
diagnost
panel
link
clinic
decis
support
tool
could
use
predict
diseas
sever
patient
suffer
infect
addit
new
pointofcar
diagnost
panel
decis
tool
app
envis
immedi
releas
help
clinician
next
week
manag
patient
design
fabric
singleus
dispos
pbnc
cartridg
equip
dedic
biohazard
wast
reservoir
use
studi
publish
previous
summar
cartridg
compris
injectionmold
fluidic
bodi
lamin
cap
layer
top
bottom
side
upper
cap
layer
pattern
fluidic
channel
throughhol
aluminum
blister
pack
bond
cartridg
upper
dsa
doubl
side
adhes
layer
super
hydrophob
polyvinyliden
fluorid
pvdf
membran
emd
millipor
billerica
debri
filter
made
nuclepor
tracketch
membran
ge
healthcar
fairfield
ct
polyethylen
terephthal
pet
cap
layer
cover
remain
expos
adhes
fulli
integr
pointofcar
instrument
describ
previous
current
studi
instrument
configur
modular
fixtur
experiment
assay
develop
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
thread
len
tube
adapt
thorlab
inc
newton
nj
mount
onto
machin
aluminum
support
base
excit
light
provid
led
tcube
led
driver
thorlab
inc
newton
nj
optic
filter
includ
singleband
bandpass
emiss
filter
semrock
inc
rochest
new
york
excit
filter
dichroic
mirror
edmund
optic
barrington
nj
imag
captur
camera
soni
cmo
sensor
point
grey
research
inc
richmond
british
columbia
canada
control
softwar
user
interfac
develop
natick
multiplex
immunoassay
develop
subset
propos
biomark
demonstr
proof
concept
diseas
sever
panel
spheric
agaros
sensor
bead
crosslink
synthes
use
method
previous
report
bead
sort
narrow
size
distribut
use
test
siev
crosslink
glyoxal
activ
activ
bead
function
analytespecif
captur
antibodi
use
reduct
amin
sodium
cyanoborohydrid
follow
deactiv
unreact
site
tri
buffer
sodium
cyanoborohydrid
ctni
ntprobnp
antibodi
standard
purchas
hytest
ltd
cartridg
manual
popul
bead
sensor
conjug
pad
reagent
bead
sensor
strateg
configur
design
locat
within
bead
support
chip
spatial
identif
detect
antibodi
spot
onto
glass
fiber
conjug
pad
emd
millipor
billerica
insert
cartridg
assay
perform
direct
sandwichtyp
immunoassay
format
room
temperatur
assay
sampl
wet
sensor
array
second
sampl
deliv
minut
follow
second
wash
detect
antibodi
elut
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
reagent
pad
minut
flow
pb
pad
origin
blister
follow
final
wash
use
ramp
flow
rate
total
time
assay
approxim
minut
consum
total
volum
imag
analyz
use
custom
imag
analysi
tool
develop
matlab
describ
previous
fluoresc
respons
bead
express
averag
pixel
intens
region
interest
limit
outer
bead
diamet
specif
signal
concentr
bead
sensor
optic
obstruct
debri
bubbl
exclud
analysi
likewis
fail
assay
run
due
leak
reject
reassay
curv
fit
routin
process
bead
arrang
columnbycolumn
chip
two
mouseantibodi
sensit
bead
place
silicon
coat
releas
liner
remov
chip
optic
cover
bond
expos
underli
adhes
seal
analysi
chamber
cocktail
ctni
ckmb
myo
ntprobnp
standard
prepar
goat
serum
meridian
life
scienc
concentr
ngml
standard
solut
process
pbnc
assay
system
triplic
respons
determin
five
matrix
blank
sampl
also
process
determin
variat
blank
respons
upper
end
assay
rang
determin
highest
concentr
achiev
without
satur
sensor
bead
studi
involv
develop
sever
score
use
similar
method
describ
previous
biomark
data
hospit
patient
deriv
recent
studi
wuhan
china
patient
assign
two
outcom
patient
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
discharg
patient
die
lasso
logist
regress
model
train
use
follow
predictor
age
sex
ctni
crp
pct
myo
maximum
biomark
valu
across
time
point
extract
patient
log
transform
data
standard
zero
mean
unit
varianc
miss
data
imput
use
multivari
imput
chain
equat
mice
algorithm
statist
softwar
r
ten
imput
gener
use
predict
mean
match
logist
regress
imput
model
numer
categor
data
respect
data
partit
use
stratifi
crossvalid
preserv
rel
proport
outcom
fold
model
train
select
perform
imput
dataset
model
select
penalti
paramet
correspond
one
standard
error
minimum
devianc
addit
shrinkag
model
perform
document
term
auc
median
interquartil
rang
iqr
sever
score
patient
die
versu
recov
use
pool
estim
sever
score
crossvalid
pool
imput
data
set
inform
boxplot
scatterplot
biomark
valu
score
compar
discharg
patient
vs
die
use
wilcoxon
rank
sum
test
age
compar
use
independ
ttest
proport
compar
use
chisquar
test
twosid
test
consid
statist
signific
level
extern
valid
sever
score
data
case
studi
hospit
patient
shenzhen
china
result
present
scatterbox
plot
sever
score
three
group
patient
defin
follow
moder
patient
whose
complic
pneumonia
sever
patient
pneumonia
ard
critic
patient
one
sever
ard
respiratori
failur
cardiac
failur
shock
biomark
profil
patient
chang
timelin
infect
therefor
need
seri
diagnost
test
collect
covermonitor
entir
timelin
infect
three
test
relev
first
molecular
diagnost
test
viru
part
test
includ
rtpcr
immunolog
test
specif
compon
viru
coronaviru
spike
glycoprotein
assay
modal
lend
inform
amount
viru
present
initi
stage
infect
ie
day
lack
accur
quantit
inform
sampl
often
collect
nasal
swab
sampl
volum
illdefin
initi
infect
phase
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
viru
becom
suppress
due
activ
humor
respons
host
involv
product
antiviru
specif
antibodi
second
relev
diagnost
test
involv
detect
antibodi
respons
indic
exposur
subsequ
immun
respons
viru
humor
immun
respons
usual
begin
product
igm
antibodi
igm
antibodi
tend
low
affin
sinc
produc
b
cell
undergo
somat
hypermut
howev
igm
pentamer
structur
make
effect
activ
complement
system
import
control
infect
bloodstream
monomer
igg
domin
later
phase
antibodi
respons
test
coronaviru
exposur
immun
respons
use
viral
antigen
detect
antibodi
bloodstream
throughout
timelin
would
benefit
care
decis
plan
resourc
alloc
identifi
highrisk
patient
underli
ongo
past
medic
condit
sooner
patient
identifi
better
prognosi
stabil
measur
close
monitor
highlight
introduct
one
major
diagnost
gap
focu
paper
determin
diseas
sever
third
relev
diagnost
test
associ
initi
report
suggest
associ
sever
diseas
requir
intens
care
approxim
proven
infect
report
chines
center
diseas
control
prevent
state
case
fatal
rate
higher
cardiovascular
diseas
diabet
chronic
respiratori
diseas
hypertens
cancer
grow
evid
suggest
interact
cardiovascular
system
multipl
level
increas
morbid
mortal
underli
cardiovascular
condit
evid
myocardi
injuri
observ
higher
rate
die
studi
patient
patient
normal
cardiac
troponin
level
without
cardiovascular
diseas
die
versu
patient
elev
ctnt
cardiovascular
diseas
underli
health
patient
strong
associ
outcom
must
includ
clinic
decis
support
tool
determin
diseas
sever
perspect
mind
develop
portabl
assay
system
suitabl
diseas
sever
would
extrem
import
come
week
month
global
pandem
move
forward
given
broad
spectrum
diseas
sever
rapid
clinic
declin
patient
develop
pneumonia
andor
cardiac
injuri
pointofcar
assay
decis
support
system
could
improv
triag
patientsand
eventu
outcomesfor
need
immedi
aggress
care
incorpor
calcul
sever
score
electron
health
record
ehr
would
provid
health
provid
action
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
inform
earli
stage
resourc
focus
patient
expect
sever
affect
measur
protein
includ
score
either
provid
ehr
integr
pointofcar
biosensor
system
describ
collect
multipl
separ
test
platform
wide
use
ehr
support
construct
custommad
decis
support
system
allow
fast
implement
sever
score
base
current
avail
method
measur
protein
use
calcul
score
ehr
integr
pointofcar
biosensor
system
follow
later
valid
indic
stepwis
approach
allow
fast
deploy
sever
score
follow
increas
test
throughput
implement
pointofcar
biosensor
system
allow
better
triag
patient
allow
scarc
healthcar
resourc
focus
patient
risk
develop
sever
symptom
pbnc
pointofcar
biosensor
system
capac
learn
adapt
applic
diseas
sever
figur
highlight
key
diagnost
infrastructur
requir
complet
integr
biomark
assay
need
establish
sever
score
small
amount
patient
sampl
serum
cartridg
instrument
perform
multistep
assay
sequenc
digit
biolog
convert
fluoresc
immunoassay
signal
biomark
concentr
statist
learn
algorithm
train
data
biomark
studi
predict
spectrum
diseas
result
singl
valu
score
display
patient
provid
mobil
health
app
directli
instrument
complet
test
previous
publish
gener
framework
implement
pointofcar
base
clinic
decis
support
system
adapt
method
task
predict
mortal
patient
emphas
integr
test
sever
score
report
articul
repres
arguabl
effici
deliveri
mode
scale
regulatori
approv
test
ecosystem
take
sever
month
complet
immin
arriv
peak
pandem
import
emphas
sever
score
gener
immedi
use
biomark
measur
collect
multipl
separ
test
platform
anticip
contribut
could
immedi
impact
patient
manag
plan
promptli
distribut
sever
score
capabl
follow
addit
model
refin
valid
select
biomark
target
develop
sever
score
base
follow
processcriteria
summar
tabl
biomark
identifi
relev
complic
associ
includ
associ
acut
inflammationinfect
crp
variou
stage
cardiovascular
diseas
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
coronari
arteri
diseas
crp
pct
acut
myocardi
infarct
ctni
myoglobin
congest
heart
failur
ntpro
bnp
ddimer
biomark
pct
aid
decis
make
antibiot
therapi
hospit
patient
patient
suspect
confirm
lower
respiratori
tract
infect
includ
communityacquir
pneumonia
acut
bronchiti
acut
exacerb
chronic
obstruct
pulmonari
diseas
also
select
valuabl
tool
pandem
identifi
patient
risk
bacteri
coinfect
advers
outcom
importantli
select
biomark
reportedli
shown
exhibit
signific
differ
level
patient
recov
vs
die
although
pbnc
design
accommod
solubl
cellular
target
use
either
bead
membranebas
assay
configur
respect
opt
sole
focu
solubl
protein
biomark
restrict
biomark
choic
complementari
concentr
rang
stabl
allow
simultan
measur
though
lymphocyt
cytokin
associ
mortal
neither
two
class
analyt
select
incompat
select
criteria
complementari
assay
panel
diseas
sever
index
describ
surveil
panel
featur
futur
public
shown
along
relev
immunoschemat
figur
briefli
beadbas
test
sever
index
panel
target
simultan
measur
six
design
protein
compat
multiplex
detect
direct
sandwich
immunoassay
involv
six
match
pair
capturedetect
antibodi
six
biomark
first
captur
correspond
bead
specif
detect
via
match
alexa
fluor
detect
antibodi
present
bead
array
develop
fulli
quantit
assay
control
experi
conduct
ensur
crosstalk
interfer
assay
multiplex
immunoassay
develop
subset
propos
biomark
demonstr
proof
concept
diseas
sever
panel
pbnc
platform
perform
power
quantit
multiplex
measur
extend
rang
calibr
curv
necessari
quantit
concentr
molecular
target
solut
critic
input
diagnost
algorithm
figur
demonstr
capabl
four
simultan
gener
calibr
curv
ctni
ckmb
myo
ntprobnp
cover
concentr
rang
ngml
error
bar
indic
beadtobead
precis
four
redund
bead
measur
per
sensor
class
shown
respons
data
biomark
exhibit
excel
fit
fiveparamet
logist
regress
part
multiplex
assay
develop
effort
specif
confirm
fourplex
panel
shown
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
inset
imag
figur
singl
antigen
standard
high
concentr
process
cartridg
configur
multiplex
detect
expect
monoclon
antibodi
highli
specif
target
antigen
high
dose
singl
antigen
gener
minim
crossreact
nontarget
sensor
although
work
repres
subset
full
panel
cartridg
facilit
multiplex
differ
biomark
easili
expand
accommod
panel
test
valid
control
anticip
one
select
six
biomark
may
drop
addit
clinic
data
use
optim
final
sever
score
due
redund
patient
discrimin
inform
afford
biomark
identifi
method
measur
strateg
biomark
multiplex
panel
next
step
involv
translat
test
valu
alongsid
key
clinic
metric
inform
relev
diseas
sever
diseas
sever
model
develop
base
data
hospit
patient
wuhan
china
patient
hypertens
admit
hospit
eventu
discharg
die
tabl
summar
patient
characterist
lab
valu
patient
group
interestingli
male
account
death
vs
discharg
patient
studi
find
significantli
higher
level
biomark
ctni
ckmb
myo
crp
pct
patient
die
vs
discharg
likewis
age
statist
signific
factor
mean
sd
discharg
die
group
respect
sever
score
train
intern
valid
base
subset
target
biomark
ctni
pct
myo
crp
age
sex
diseas
discrimin
potenti
display
figur
analysi
sever
score
shown
two
patient
group
patient
recov
vs
pass
away
complic
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
one
limit
studi
patient
train
dataset
hypertens
thu
elev
risk
cardiovascular
event
sinc
test
panel
contain
sever
cardiac
biomark
possibl
train
data
could
lead
overoptimist
result
howev
addit
cardiac
biomark
expand
biomark
panel
repres
divers
pathophysiolog
ie
indic
infect
inflamm
mortal
thrombot
event
rhabdomyolysi
potenti
significantli
improv
generaliz
plan
evalu
optim
sever
score
model
extern
data
place
despit
limit
preliminari
result
demonstr
strong
promis
sever
score
report
preliminari
find
critic
import
given
stage
pandem
previous
use
pbnc
platform
develop
variou
well
diseas
sever
score
oral
cancer
cardiac
heart
diseas
shown
figur
final
evalu
sever
score
data
case
studi
hospit
patient
figur
present
scatterbox
plot
sever
score
three
group
patient
sever
score
found
increas
diseas
sever
moder
patient
whose
complic
pneumonia
sever
patient
pneumonia
ard
critic
patient
one
sever
ard
respiratori
failur
cardiac
failur
shock
group
median
iqr
sever
score
respect
although
analysi
evalu
small
sampl
patient
preliminari
result
show
potenti
sever
score
calibr
diseas
sever
scale
addit
crosssect
populationbas
comparison
sever
score
could
also
use
longitudin
monitor
patient
manner
individu
time
seri
measur
could
use
track
chang
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
biomarkerbas
sever
score
time
preliminari
find
figur
demonstr
averag
trajectori
decreas
discharg
group
increas
die
group
suggest
sever
score
could
provid
valuabl
lead
time
discharg
patient
low
risk
earlier
priorit
care
elev
risk
mortal
futur
effort
use
defin
variou
decis
cut
point
refer
rang
chang
score
help
guid
clinic
decis
make
includ
therapi
decis
futur
effort
may
also
adapt
clinic
decis
support
tool
ard
result
infecti
viral
agent
influenza
varicellazost
bacteria
mycoplasma
chlamydia
legionella
parasit
malaria
caus
plasmodium
falciparum
studi
establish
framework
pointofcar
sever
score
clinic
decis
support
system
studi
find
median
sever
score
significantli
lower
group
recov
versu
group
die
complic
versu
respect
auc
valu
sever
score
demonstr
strong
potenti
util
identifi
patient
increas
risk
mortal
plan
place
confirm
final
select
biomark
integr
pointofcar
sever
score
diseas
sever
test
possibl
biomark
may
yield
redund
inform
redund
biomark
may
elimin
creat
sparser
diagnost
panel
improv
generaliz
labonachip
diagnost
capabl
potenti
yield
first
quantit
pointofcar
diagnost
panel
link
clinic
decis
support
tool
predict
mortal
experienc
team
establish
translat
partnership
place
move
system
realworld
practic
time
manner
releas
app
immedi
impact
patient
manag
next
week
anticip
futur
work
may
also
involv
develop
test
platform
populationbas
commun
surveil
clinic
set
ambul
hospit
clinic
laboratori
public
set
risk
commun
spread
busi
school
airport
train
station
develop
distribut
portabl
afford
wide
distribut
smart
sensor
technolog
anticip
availabilityreadi
within
month
promis
import
solut
manag
current
coronaviru
crisi
well
adapt
tool
combat
futur
threat
new
viru
biolog
threat
likewis
addit
sever
score
sustain
contribut
work
may
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
develop
ard
clinic
decis
support
tool
infecti
viral
agent
bacteria
parasit
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
two
panel
detail
diseas
sever
panel
featur
work
b
commun
exposur
surveil
panel
describ
futur
effort
c
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
figur
sever
score
evalu
case
studi
hospit
patient
shenzhen
china
moder
group
contain
patient
whose
complic
pneumonia
sever
group
patient
pneumonia
ard
critic
group
contain
patient
one
sever
ard
respiratori
failur
cardiac
failur
shock
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
